Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Cross-protective immune-enhancing mechanisms of combined mRNA and conventional flu vaccines

Award Number: R21AI190236
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 04/22/2026
PERIOD OF PERFORMANCE END DATE: 03/31/2028

Group Awards By:

View Award Description

Cross-protective immune-enhancing mechanisms of combined mRNA and conventional flu vaccines - Project Summary Hemagglutinin (HA) antigenic changes of influenza (flu) viruses and low immunogenicity of conventional flu vaccines result in suboptimal efficacy, ranging between 10% and 60%, and much lower efficacy or no protection against pandemics. It is a high priority to design new universal flu vaccines, develop a novel vaccination strategy, and better understand the innate and adaptive immune mechanisms for vaccine- mediated effective protection. The mRNA vaccine platform would provide many advantages over conventional vaccines. In this project, we designed new mRNA vaccine constructs encoding neuraminidase (NA) conjugated to a highly conserved M2e repeat, which is based on our prior studies reporting that immunity to both NA and M2e could provide broad cross-protection against different subtypes and lineages of flu A and flu B viruses. However, non-neutralizing immunity to conserved domains would have limited efficacy despite broader protection. Lipid nanoparticles (LNP) encapsulating mRNA vaccines are known to be inflammatory. High doses of mRNA LNP vaccines would cause undesirable side effects. We hypothesize that mRNA LNP vaccine targeting conserved domains and inducing cross-protective immunity will enhance the broad cross- protection of co-administered conventional flu split vaccines at low doses of both vaccines. This hypothesis is supported by our new preliminary data demonstrating that a combination of flu A 5xM2e mRNA or B NA mRNA LNP and inactivated split virus vaccines significantly enhanced the efficacy of cross-protection against flu A and flu B viruses. Flu A (not flu B) has pandemic threats, more diverse natural hosts, and antigenic diversity, and is highly pathogenic, rendering flu A viruses more challenging to control than flu B. In Specific Aim 1, we will further test the hypothesis that the combination of new cross-protective mRNA LNP and inactivated flu A virus split vaccines will provide higher efficacy of homologous and heterologous against flu A viruses. In addition, we do not fully understand the innate and adaptive immune mechanisms of how adding an mRNA LNP vaccine to conventional inactivated split virus vaccination will enhance homologous and heterologous protection. In Specific Aim 2, we will determine whether a combination of an mRNA LNP vaccine and conventional inactivated flu split vaccines will activate a unique set of innate immune responses leading to enhanced adaptive immunity. We expect that the outcomes of this project will provide insight into innate and adaptive immune correlates with enhanced homo- and cross-protection by a combination of cross-protective mRNA and conventional vaccines, in addition to developing a new vaccination strategy inducing enhanced protection against seasonal and pandemic potential variants.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $197,500 )
2026	2026	GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION INC	58 EDGEWOOD AVE NE	ATLANTA	GA	30303	FULTON	USA	Allergy and Infectious Diseases Research	000	1	4/27/2026	NEW	$197,500
														Subtotal = $197,500

Grand Total All Awards = $197,500

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Cross-protective immune-enhancing mechanisms of combined mRNA and conventional flu vaccines

Award Number: R21AI190236

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 04/22/2026

PERIOD OF PERFORMANCE END DATE: 03/31/2028

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer